Mardepodect

Mardepodect

• CAS Number: 898562-94-2
• UNSPSC Description: Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier[1][2].
• Target Antigen: Phosphodiesterase (PDE)
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/PF-2545920.html
• Purity: 99.04
• Solubility: DMSO : ≥ 45 mg/mL
• Smiles: CN(N=C1C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C=C1C5=CC=NC=C5
• Molecular Weight: 392.45
• References & Citations: [1]Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem, 2009, 52(16), 5188-5196.|[2]Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331(2), 574-590.Toxicol Appl Pharmacol. 2024 Apr 28:486:116945.|Patent. US20230111925A1.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Phase 2